MIR5193: A Potential Drug Target and Biomarker (G100847079)

Target Name: MIR5193

NCBI ID: G100847079

MIR5193

Other Name(s): mir-5193 | microRNA 5193 | MicroRNA 5193 | hsa-miR-5193 | hsa-mir-5193

MIR5193: A Potential Drug Target and Biomarker

MIR5193, a gene encoding a protein known as CD28 superagonist, has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases.

The CD28 superagonist protein is a type of costimulin that is expressed in many different tissues and cells in the body. It is known to play a critical role in the regulation of T cell responses and has been implicated in various immune and inflammatory processes. MIR5193 has four potential transmembrane domains, including an extracellular domain that is involved in cell-cell interactions and a cytoplasmic tail that is involved in intracellular signaling.

One of the most significant features of MIR5193 is its ability to interact with multiple cell surface molecules, including CD28, a protein that is known to play a critical role in the regulation of T cell responses. CD28 is a glycoprotein that is expressed in high levels in T cells and is involved in the regulation of cell expansion, differentiation, and survival. MIR5193 has been shown to interact with CD28 and can modulate its activity, suggesting that it may be a useful drug target for the treatment of T cell-related diseases.

In addition to its potential role in T cell responses, MIR5193 has also been shown to be involved in the regulation of cell adhesion and migration. It is known to play a critical role in the formation of tight junctions, which are a type of cell-cell adhesion that is important for the regulation of cell behavior and the development of tissues. MIR5193 has also been shown to be involved in the regulation of cell migration, which is critical for the development and progression of tissues and organs.

MIR5193 has also been shown to be involved in the regulation of cell survival and stress responses. It is known to play a critical role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death in response to environmental stressors, such as UV radiation, chemicals, or infections. MIR5193 has also been shown to play a critical role in the regulation of cell stress responses, including the regulation of the production of reactive oxygen species (ROS) and the detoxification of ROS.

In addition to its role in cell signaling, MIR5193 has also been shown to have potential as a drug target for the treatment of various diseases. For example, it has been shown to be involved in the regulation of cancer cell growth and has been identified as a potential drug target for the treatment of breast cancer. In addition, MIR5193 has been shown to be involved in the regulation of autoimmune disorders, including the regulation of the production of autoantibodies and the regulation of the activation and activity of T cells.

MIR5193 has also been shown to be involved in the regulation of neurodegenerative diseases, including the regulation of the production of neurotransmitters and the regulation of the structure and function of neural circuits. For example, MIR5193 has been shown to play a critical role in the regulation of the production of dopamine, a neurotransmitter that is involved in the regulation of mood, motivation, and appetite. In addition, MIR5193 has been shown to play a critical role in the regulation of the structure and function of neural circuits, including the regulation of the formation and maintenance of synapses.

In conclusion, MIR5193 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and function, as well as its ability to interact with multiple cell surface molecules, including CD

Protein Name: MicroRNA 5193

The "MIR5193 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5193 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets